tetano
Editor, Senior Moderator
Nat Commun
. 2021 Aug 11;12(1):4864.
doi: 10.1038/s41467-021-25113-5.
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
Katie L Kunze[SUP] #[/SUP][SUP] 1 [/SUP], Patrick W Johnson[SUP] #[/SUP][SUP] 2 [/SUP], Noud van Helmond[SUP] 3 [/SUP], Jonathon W Senefeld[SUP] 4 [/SUP], Molly M Petersen[SUP] 1 [/SUP], Stephen A Klassen[SUP] 4 [/SUP], Chad C Wiggins[SUP] 4 [/SUP], Allan M Klompas[SUP] 4 [/SUP], Katelyn A Bruno[SUP] 5 [/SUP], John R Mills[SUP] 6 [/SUP], Elitza S Theel[SUP] 6 [/SUP], Matthew R Buras[SUP] 1 [/SUP], Michael A Golafshar[SUP] 1 [/SUP], Matthew A Sexton[SUP] 4 [/SUP], Juan C Diaz Soto[SUP] 4 [/SUP], Sarah E Baker[SUP] 4 [/SUP], John R A Shepherd[SUP] 4 [/SUP], Nicole C Verdun[SUP] 7 [/SUP], Peter Marks[SUP] 7 [/SUP], Nigel S Paneth[SUP] 8 9 [/SUP], DeLisa Fairweather[SUP] 5 [/SUP], R Scott Wright[SUP] 10 11 [/SUP], Camille M van Buskirk[SUP] 6 [/SUP], Jeffrey L Winters[SUP] 6 [/SUP], James R Stubbs[SUP] 6 [/SUP], Katherine A Senese[SUP] 4 [/SUP], Michaela C Pletsch[SUP] 4 [/SUP], Zachary A Buchholtz[SUP] 4 [/SUP], Robert F Rea[SUP] 10 [/SUP], Vitaly Herasevich[SUP] 4 [/SUP], Emily R Whelan[SUP] 5 [/SUP], Andrew J Clayburn[SUP] 4 [/SUP], Kathryn F Larson[SUP] 10 [/SUP], Juan G Ripoll[SUP] 4 [/SUP], Kylie J Andersen[SUP] 4 [/SUP], Elizabeth R Lesser[SUP] 2 [/SUP], Matthew N P Vogt[SUP] 4 [/SUP], Joshua J Dennis[SUP] 4 [/SUP], Riley J Regimbal[SUP] 4 [/SUP], Philippe R Bauer[SUP] 12 [/SUP], Janis E Blair[SUP] 13 [/SUP], Arturo Casadevall[SUP] 14 [/SUP], Rickey E Carter[SUP] 2 [/SUP], Michael J Joyner[SUP] 15 [/SUP]
Affiliations
Abstract
Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.
. 2021 Aug 11;12(1):4864.
doi: 10.1038/s41467-021-25113-5.
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
Katie L Kunze[SUP] #[/SUP][SUP] 1 [/SUP], Patrick W Johnson[SUP] #[/SUP][SUP] 2 [/SUP], Noud van Helmond[SUP] 3 [/SUP], Jonathon W Senefeld[SUP] 4 [/SUP], Molly M Petersen[SUP] 1 [/SUP], Stephen A Klassen[SUP] 4 [/SUP], Chad C Wiggins[SUP] 4 [/SUP], Allan M Klompas[SUP] 4 [/SUP], Katelyn A Bruno[SUP] 5 [/SUP], John R Mills[SUP] 6 [/SUP], Elitza S Theel[SUP] 6 [/SUP], Matthew R Buras[SUP] 1 [/SUP], Michael A Golafshar[SUP] 1 [/SUP], Matthew A Sexton[SUP] 4 [/SUP], Juan C Diaz Soto[SUP] 4 [/SUP], Sarah E Baker[SUP] 4 [/SUP], John R A Shepherd[SUP] 4 [/SUP], Nicole C Verdun[SUP] 7 [/SUP], Peter Marks[SUP] 7 [/SUP], Nigel S Paneth[SUP] 8 9 [/SUP], DeLisa Fairweather[SUP] 5 [/SUP], R Scott Wright[SUP] 10 11 [/SUP], Camille M van Buskirk[SUP] 6 [/SUP], Jeffrey L Winters[SUP] 6 [/SUP], James R Stubbs[SUP] 6 [/SUP], Katherine A Senese[SUP] 4 [/SUP], Michaela C Pletsch[SUP] 4 [/SUP], Zachary A Buchholtz[SUP] 4 [/SUP], Robert F Rea[SUP] 10 [/SUP], Vitaly Herasevich[SUP] 4 [/SUP], Emily R Whelan[SUP] 5 [/SUP], Andrew J Clayburn[SUP] 4 [/SUP], Kathryn F Larson[SUP] 10 [/SUP], Juan G Ripoll[SUP] 4 [/SUP], Kylie J Andersen[SUP] 4 [/SUP], Elizabeth R Lesser[SUP] 2 [/SUP], Matthew N P Vogt[SUP] 4 [/SUP], Joshua J Dennis[SUP] 4 [/SUP], Riley J Regimbal[SUP] 4 [/SUP], Philippe R Bauer[SUP] 12 [/SUP], Janis E Blair[SUP] 13 [/SUP], Arturo Casadevall[SUP] 14 [/SUP], Rickey E Carter[SUP] 2 [/SUP], Michael J Joyner[SUP] 15 [/SUP]
Affiliations
- PMID: 34381030
- DOI: 10.1038/s41467-021-25113-5
Abstract
Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Evidence that SARS-CoV-2 exists as locally evolving variants suggests that immunological differences may impact the effectiveness of antibody-based treatments such as convalescent plasma and vaccines. Considering that near-sourced convalescent plasma likely reflects the antigenic composition of local viral strains, we hypothesize that convalescent plasma has a higher efficacy, as defined by death within 30 days of transfusion, when the convalescent plasma donor and treated patient were in close geographic proximity. Results of a series of modeling techniques applied to approximately 28,000 patients from the Expanded Access to Convalescent Plasma program (ClinicalTrials.gov number: NCT04338360) support this hypothesis. This work has implications for the interpretation of clinical studies, the ability to develop effective COVID-19 treatments, and, potentially, for the effectiveness of COVID-19 vaccines as additional locally-evolving variants continue to emerge.